Generic Drugs: First-Cycle Review Times Improve, But Hundreds Of ANDAs Still Pending
Executive Summary
US FDA cut first-cycle review time 46% between fiscal year 2013 and FY 2015, but more than 900 ANDAs still awaited review by end of 2016.
You may also be interested in...
Is ANDA Bolus Coming As Higher User Fees Loom?
Generic submission volume remained steady in August as some wonder whether sponsors will rush to avoid a 144% increase in the ANDA user fee taking effect Oct. 1.
Is ANDA Bolus Coming As Higher User Fees Loom?
Generic submission volume remained steady in August as some wonder whether sponsors will rush to avoid a 144% increase in the ANDA user fee taking effect Oct. 1.
Mylan Suggests Downside To FDA's Efforts To Improve Generic Drug Review
Company says that while FDA has focused on expediting approval of third and fourth generics, it has not done so for first generics and complex products.